Clinical Trial Update: Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of AUTO3, a CD19/CD22 CAR T-cell therapy, for relapsed/refractory diffuse large B-cell lymphoma; the trial has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• AUTO3 CD19/CD22 CAR T cells (AUTO3)

Snippet

Sponsor: Autolus Limited | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-07-14